30489-47-5Relevant academic research and scientific papers
ORAL COMPLEMENT FACTOR D INHIBITORS
-
Page/Page column 202; 203, (2021/04/17)
Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
-
Page/Page column 61; 62; 63, (2017/05/10)
This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidaz
2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE
-
Paragraph 1292, (2015/11/27)
The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.
